Bilateral primary breast lymphoma in a teenage girl with multi-organ involvement
View/ Open
Date
2013Author
Poureisa, M
Daghighi, MH
Mazaheri-Khameneh, R
Ghadirpour, A
Metadata
Show full item recordAbstract
We present 16 years old girl with primary breast lymphoma involving the both breasts simultaneously and co-incidence of central nervous system (CNS) involvement which originated from the breast, in addition to evidence of lymphoma in multi-organ such as skin, mediastinum and some abdominal viscera. Bilaterality has been observed in some series, but reports are few and series are often very small. Radiologic features may be indistinguishable from those of the other breast malignancies, but it can be concluded that primary involvement of the breast with lymphoma should be considered when breast mass or inflammatory changes occur in a patient without any previously diagnosed lymphoma. The clinical behavior, imaging and therapeutic procedures are discussed. The findings of this report may have clinical impact on oncologists or that may alter the disease concept of bilateral breast lymphoma. é 2013 Tehran University of Medical Sciences. All rights reserved.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Target therapy of cancer: Implementation of monoclonal antibodies and nanobodies
Majidi, J; Barar, J; Baradaran, B; Abdolalizadeh, J; Omidi, Y (2009)In the past decades, the mainstay of systemic therapy for solid and haematological malignancies was chemotherapy; nevertheless this modality has the drawbacks such as drug resistance and eliciting sever cytotoxicity in the ... -
Recombinant human erythropoietin in children with solid tumors and chemotherapy-induced anemia
Ataollah Hiradfar, A; Rezamand, A; Pourghasem, M; Karkon Shayan, S; Ghamari, B; Karkon Shayan, F (2018)Background: In patients undergoing chemotherapy for cancer, anemia is part of the progression of the disease. Considering the effects of anemia on quality of life of the patients, the prevention and treatment of ... -
A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections.
Seyfizadeh, N; Seyfizadeh, N; Hasenkamp, J; Huerta-Yepez, S (2016)Rituximab (a chimeric anti-CD20 monoclonal antibody) is the first Food and Drug Administration approved anti-tumor antibody. Immunotherapy by rituximab, especially in combination-therapy, is a mainstay for a vast variety ...